Oligopeptide transport protein of prevotella and application of oligopeptide transport protein

By strengthening the expression of the Prevotella P.copri oligopeptide transporter Pc-OPT in Escherichia coli EcN, the problem of insufficient intestinal colonization ability of EcN was solved, and its colonization ability and oligopeptide in the intestinal tract was significantly improved. Metabolic ability improves intestinal adaptability.

CN118955660AActive Publication Date: 2024-11-15YANGZHOU UNIV
View PDF 6 Cites 0 Cited by

Patent Information

Application Number
CN202410938329.6
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-13
Publication Date
2024-11-15
Estimated Expiration
2044-07-13

AI Technical Summary

Technical Problem

The intestinal colonization ability of E. coli EcN is weak, limiting its long-term colonization and disease treatment effect in the intestinal tract.

Method used

In EcN, the oligopeptide transporter Pc-OPT derived from Prevotella P.copri was enhanced to enhance its oligopeptide transport ability and intestinal colonization ability.

Benefits of technology

By strengthening the expression of Pc-OPT, the colonization ability of EcN-Pc-OPT strain in the intestine of mice was significantly improved, which enhanced its metabolic ability to intestinal nutrients and promoted intestinal adaptability and colonization.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118955660A_ABST
    Figure CN118955660A_ABST
Patent Text Reader

Abstract

The invention discloses an oligopeptide transport protein of prevotella and application thereof. The oligopeptide transport protein has an amino acid sequence as shown in SEQ ID NO. 1. The oligopeptide transport protein Pc-OPT derived from P.copri is obtained through identification, and after the oligopeptide transport protein Pc-OPT is subjected to enhanced expression in EcN, the oligopeptide transport capacity of the EcN can be improved. Furthermore, after the strain with the high oligopeptide transport capacity is subjected to intragastric administration to a C57BL / 6J mouse, the colonization time of the strain in the intestinal tract of the mouse is obviously prolonged. The results show that the oligopeptide in the intestinal tract can be better utilized by enhancing the oligopeptide transport capacity of the EcN, so that the intestinal tract adaptability and colonization capacity of the EcN are improved.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the field of microbial metabolic transformation, and specifically relates to an oligopeptide transporter of Prevotella and an application thereof. Background Art

[0002] The spatial distribution, relative abundance and function of intestinal microorganisms in the intestine are crucial to the health of the host and the maintenance of physiological and metabolic homeostasis. The composition of intestinal microorganisms is affected by the host's age, gender, genotype, living environment, diet and antibiotics. Among them, diet is an important factor affecting intestinal microorganisms. The type, quantity and balance of its nutrients will affect the composition and structure of intestinal microorganisms. Among these nutrients, oligopeptides are small molecule nutrients produced by the degradation of food-derived proteins and widely distributed in the host's intestine. Studies have shown that more intestinal microorganisms (such as Lactobacillus) can metabolize oligopeptides to improve their intestinal colonization ability.

[0003] Prevotella copri DSM 18205 (P. copri) is an anaerobic Gram-negative bacterium. On the one hand, it can exert probiotic properties by decomposing proteins and carbohydrates. On the other hand, it can also act as a conditional pathogen, causing periodontal and dental diseases, intestinal inflammation, rheumatoid arthritis, bacterial vaginitis and other diseases. Therefore, studying the metabolic characteristics of P. copri is of great significance for analyzing the pathogenesis of the above-mentioned related diseases. In the present invention, we inoculated P. copri into a PBS buffer containing intestinal metabolites for anaerobic treatment, and then used a non-targeted metabolome analysis strategy to analyze the ability of P. copri to metabolize different intestinal metabolites. The results showed that P. copri has a strong oligopeptide metabolism ability. Further, combining informatics analysis and qRT-PCR verification strategies, we identified an oligopeptide transport-related protein Pc-OPT in P. copri.

[0004] Escherichia coli Nissle 1917 (EcN) is a chassis probiotic with high safety. The engineered strains obtained by metabolic modification of EcN have been successfully used to treat a series of metabolic diseases and neurodegenerative diseases, and some research results have entered the clinical trial stage. However, due to the weak intestinal colonization ability of EcN, it cannot colonize in the intestine for a long time, which greatly limits the disease treatment effect of the engineered bacteria modified by EcN. We used a non-targeted metabolome analysis strategy to analyze the metabolic characteristics of EcN. The results showed that EcN has a weak ability to metabolize oligopeptides, which indicates that the ability to metabolize oligopeptides is likely to be an important factor limiting the intestinal colonization of EcN. Based on this, in this patent, we applied the oligopeptide transporter Pc-OPT derived from P.copri in EcN. Specifically, we overexpressed the oligopeptide transporter Pc-OPT derived from P.copri in EcN to obtain the strain EcN-Pc-OPT. The oligopeptide metabolism ability of EcN-Pc-OPT was analyzed in vitro, and the results showed that the ability of EcN-Pc-OPT to metabolize tripeptides was improved. After EcN-Pc-OPT was gavaged into mice, the EcN-Pc-OPT strain in the fecal samples was quantitatively analyzed, and the results showed that the intestinal colonization ability of EcN-Pc-OPT was significantly higher than that of the control strain, indicating that the enhanced expression of the oligopeptide transporter Pc-OPT can significantly improve the intestinal colonization ability of EcN.

[0005] The present invention identified an oligopeptide transporter Pc-OPT derived from P. copri. After enhanced expression in EcN, the tripeptide transport capacity and intestinal colonization ability of EcN can be improved, which indicates that enhancing the metabolic ability of EcN for intestinal nutrients is an effective strategy to improve its intestinal colonization ability. Summary of the invention

[0006] Technical problem to be solved: The present invention provides an oligopeptide transporter of Prevotella and its application. The applicant combined bioinformatics analysis strategy to identify an oligopeptide transporter in Prevotella P.copri DSM 18205 (P.copri), named Pc-OPT (PREVCOP_RS04210), and enhanced the expression of the oligopeptide transporter gene in EcN to improve the oligopeptide transport capacity of EcN and its intestinal colonization ability.

[0007] Technical solution: An oligopeptide transporter derived from Prevotella, having an amino acid sequence as shown in SEQ ID NO.1.

[0008] A nucleic acid encoding the oligopeptide transporter from the genus Prevotella, and the nucleotide sequence thereof is shown as SEQ ID NO.2.

[0009] A plasmid comprising the above nucleic acid.

[0010] A recombinant Escherichia coli transformed to contain the plasmid described above.

[0011] The oligopeptide transporter of Prevotella is used to enhance the oligopeptide transport capacity of Escherichia coli and its intestinal colonization ability.

[0012] A pharmaceutical composition or food additive comprises the above-mentioned recombinant Escherichia coli.

[0013] A method for enhancing the intestinal colonization ability of Escherichia coli comprises the steps of: utilizing the above-mentioned recombinant Escherichia coli to enhance its colonization ability in the intestine through the oligopeptide transporter expressed by the recombinant Escherichia coli.

[0014] Beneficial effects: EcN is a probiotic related to the treatment of inflammatory bowel disease. As an excellent chassis microorganism, it is metabolically modified to construct a series of engineered bacteria related to disease treatment. However, due to the weak intestinal colonization ability of EcN, it cannot colonize in the intestine for a long time, which greatly limits the disease treatment effect of the engineered bacteria transformed by EcN. The present invention identified an oligopeptide transporter Pc-OPT derived from P. copri, which can enhance the oligopeptide transport capacity of EcN after enhanced expression in EcN. Furthermore, after the above-mentioned strain with high oligopeptide transport capacity was gavaged into C57BL / 6J mice, it was found that the colonization time of the strain in the mouse intestine was significantly increased. The above results show that enhancing the oligopeptide transport capacity of EcN can promote its better utilization of oligopeptides in the intestine, thereby increasing its intestinal adaptability and colonization ability. BRIEF DESCRIPTION OF THE DRAWINGS

[0015] Figure 1 The results of the oligopeptide metabolism ability test of E. coli EcN and Prevotella P.copri. Here, we added 1mL PBS buffer to 100mg of fecal sample, homogenized the fecal sample with PBS buffer, centrifuged it at 12000rpm for 30min, tried to remove the excess residue in the feces, and then filtered the supernatant obtained by centrifugation with a 0.22μm filter to obtain a buffer containing fecal metabolites. A is a schematic diagram of the collection of metabolites in cynomolgus monkey fecal samples and the detection of the ability of EcN and P.copri to metabolize fecal metabolites. Specifically, we suspended the EcN and P.copri cells washed with PBS in a buffer containing fecal metabolites and cultured them for 6h, then centrifuged to obtain the supernatant for non-targeted metabolome analysis; B is a schematic diagram of the detection of the ability of EcN to metabolize oligopeptides; C is a schematic diagram of the detection of the ability of P.copri to metabolize oligopeptides. The results show that P.copri has a stronger ability to metabolize oligopeptides than EcN.

[0016] Figure 2 Analysis of the expression level of the oligopeptide transporter Pc-OPT of Prevotella copri in the oligopeptide detection system PBS-oligopeptide. Specifically, we added acid hydrolyzed casein (Suoshi, C8221) and enzymatic hydrolyzed casein (Suoshi, C8210) to PBS buffer at 18.2 g / L and 8 g / L, and filtered and sterilized to obtain the oligopeptide detection system PBS-oligopeptide. After that, the P. copri bacteria washed with PBS were suspended in PBS and PBS-oligopeptide for 6 hours. After centrifugation, the bacteria were collected and RNA was extracted and reverse transcribed to obtain cDNA. Finally, real-time fluorescence quantitative PCR was used to detect the expression level of the Pc-OPT encoding gene in the two systems. A is a schematic diagram of the coding gene and function of the oligopeptide transporter Pc-OPT of Prevotella copri; B is a real-time fluorescence quantitative PCR analysis of the expression level of the P. copri oligopeptide transporter Pc-OPT in the oligopeptide detection system PBS-oligopeptide. The results showed that in the presence of oligopeptides, the expression of the Pc-OPT encoding gene in P. copri was significantly increased, suggesting that Pc-OPT is a functional oligopeptide transporter.

[0017] Figure 3 Schematic diagram of the operation of comparing the oligopeptide metabolism capacity of E. coli EcN-P and EcN-Pc-OPT in the oligopeptide detection system PBS-oligopeptide. Specifically, EcN-P and EcN-Pc-OPT bacteria were washed with PBS and suspended in the oligopeptide detection system PBS-oligopeptide. After standing for 6 hours, the supernatant was collected by centrifugation for non-targeted metabolomics detection. Finally, we will determine the oligopeptide metabolism capacity of EcN-P and EcN-Pc-OPT by analyzing the types and contents of oligopeptides in the supernatant. Here we analyze the non-targeted metabolomics results in positive and negative ion modes respectively. The oligopeptide metabolism capacity of EcN-P and EcN-Pc-OPT was compared by analyzing the types and contents of oligopeptides affected by EcN-P and EcN-Pc-OPT.

[0018] Figure 4 The oligopeptide metabolism capacity of E. coli EcN-P and EcN-Pc-OPT was compared by focusing on the types and contents of oligopeptides detected in the non-targeted metabolome. The results showed that after overexpressing Pc-OPT, the ability of the EcN-Pc-OPT strain to utilize tripeptides was significantly stronger than that of the EcN strain, suggesting that Pc-OPT is a tripeptide-specific intracellular transporter.

[0019] Figure 5BlastP was used to analyze the distribution of the oligopeptide transporter Pc-OPT of Prevotella copri in other species. Specifically, we used BlastP in NCBI to analyze the distribution of the oligopeptide transporter Pc-OPT of Prevotella copri in other species. Finally, we selected strains with identity and coverage greater than 75%, excluded redundant items according to the taxid number, and performed phylogenetic tree analysis on the selected reference sequences. The results showed that Pc-OPT is a transporter widely distributed in Prevotella and Bacteroides.

[0020] Figure 6 Results of residual bacteria in the intestine of C57BL / 6J mice 12 hours after oral administration of E. coli EcN-P and EcN-Pc-OPT. Specifically, 6-week-old male C57BL / 6J mice were intragastrically administered with PBS-oligopeptide and 1×10 10 The PBS-washed EcN-P and EcN-Pc-OPT bacteria were gavaged into mice in the manner of CFU / mouse, and the fecal samples of mice were weighed 12 hours after gavage. After the fecal samples were homogenized with PBS buffer, the obtained fecal solution was diluted and applied to LB solid plates supplemented with ampicillin resistance. After the plates were cultured at 37°C for 18 hours, the number of EcN-P and EcN-Pc-OPT strains remaining in the initial fecal solution were calculated by counting the number of colonies on the plates and the gradient dilution multiples. Finally, the corresponding number of colonies per unit fecal sample (colony number / g fecal sample) was calculated and used to determine the colonization ability of E. coli EcN-P and EcN-Pc-OPT in the mouse intestine. The results showed that the intestinal colonization ability of the EcN-Pc-OPT strain was significantly stronger than that of the EcN strain. DETAILED DESCRIPTION

[0021] The present invention will be further described below in conjunction with specific embodiments and accompanying drawings.

[0022] The present invention is further described in detail below in conjunction with the specific implementation methods and the accompanying drawings of the specification. Unless otherwise specified, the experimental methods described in the present invention are all conventional methods; the biological materials described can all be obtained from commercial channels.

[0023] Example 1: Extraction of metabolites from cynomolgus monkey fecal samples

[0024] The stool sample was homogenized with PBS buffer at a ratio of 100 mg of stool sample to 1 mL of PBS buffer, and then centrifuged at 12,000 rpm for 30 min to remove as much excess residue as possible from the stool. The supernatant obtained by centrifugation was then filtered using a 0.22 μm filter.

[0025] Example 2: Cultivation and collection of EcN and P. copri strains

[0026] EcN and P. copri strains were inoculated into YCFAG medium at a ratio of 1% and cultured at 37°C under anaerobic conditions until OD 600 =1.0. After centrifugation, the bacteria were washed three times with pre-deoxygenated PBS buffer and finally suspended in PBS buffer until OD 600 =10.

[0027] Example 3: Detection of the ability of EcN and P. copri strains to utilize metabolites in fecal samples

[0028] The EcN and P. copri bacterial suspensions obtained in Example 2 were inoculated into the PBS buffer containing fecal metabolites obtained in Example 1 at a ratio of 10%, and then cultured at 37°C for 6 hours under anaerobic conditions. After centrifugation at 12000 rpm for 30 minutes, the obtained supernatant was subjected to non-targeted metabolomics detection to determine the types and contents of metabolites in the supernatant, thereby determining the ability of EcN and P. copri strains to utilize metabolites in fecal samples.

[0029] Example 4: Preparation of oligopeptide metabolism detection system

[0030] Acid hydrolyzed casein (Suoshi, C8221) and enzymatic hydrolyzed casein (Suoshi, C8210) were added to PBS buffer at 18.2 g / L and 8 g / L, respectively, and the oligopeptide detection system PBS-oligopeptide was obtained after filtration and sterilization.

[0031] Example 5: Identification of oligopeptide transporters in P. copri strains and qRT-PCR detection of their expression levels

[0032] The P. copri strain obtained in Example 2 was inoculated into PBS and PBS-oligopeptide buffer containing oligopeptides in Example 4 at a ratio of 10%, and cultured at 37°C under anaerobic conditions for 6 hours. Collect the bacteria after centrifugation at 12000rpm for 30 minutes. Add 200μL Trizol and two small steel beads to the bacteria respectively, and then crush them in a freezing grinder (65HZ, 1min). Collect the supernatant by centrifugation at 12000rpm for 10 minutes. Add 200μL chloroform to the supernatant, vortex for 15s, and place on ice for 5min. Then, centrifuge at 4°C, 12000rpm for 5min, and take the supernatant. Add an equal volume of isopropanol to the supernatant, mix well, and precipitate at -20°C for 30min-60min. After centrifugation at 12000rpm for 10min, wash the collected precipitate twice with 1mL 75% ethanol (12000rpm, 10min). The supernatant was discarded, the precipitate was dried, and 30 μL of preheated RNAase-Free water was added to fully dissolve the RNA. Subsequently, reverse transcription was performed using PrimeScript RT Reagent Kit (TaKaRa, cat. RR047A). qRT-PCR was performed in ChemQ SYBR color qPCR Master Mix (Vazyme, Q421-02-AA) under the following conditions: 95°C for 2 minutes, followed by 40 cycles of 95°C for 15 seconds, 55°C for 20 seconds, and 72°C for 20 seconds. Bacterial 16S rRNA primers were used as internal references. The primers used are shown in Primer List 1.

[0033] Table 1 Primer information for amplifying target genes

[0034]

[0035] Example 6: Enhanced expression of P. copri-derived oligopeptide transporter in EcN

[0036] The oligopeptide transporter Pc-OPT from P. copri was amplified and then the amplified fragment was linked to the promoter P bio Connect and get P bio -Pc-OPT construct, promoter P bio The sequence is shown in SEQ ID NO. 3. Finally, construct P bio -Pc-OPT was cloned into the expression vector pET-32a to obtain the overexpression plasmid pET-32a-P bio -Pc-OPT. bio-Pc-OPT plasmid was electroporated into EcN to obtain strain EcN-Pc-OPT. In addition, pET-32a empty plasmid was electroporated into EcN to obtain strain EcN-P (this is a control strain containing an empty plasmid).

[0037] Example 7: Detection of oligopeptide metabolic capacity of strains EcN-P and EcN-Pc-OPT

[0038] In an anaerobic chamber, strains EcN-P and EcN-Pc-OPT were inoculated into LB liquid medium supplemented with 100 μg / ml ampicillin, and the OD 600 =1.0, the cells were collected, washed three times with PBS, and then suspended with PBS to a concentration of OD 600 =10; the suspended bacteria were inoculated into the deoxygenated oligopeptide detection system PBS-oligopeptide in Example 4 at a ratio of 10%, and the supernatant was collected by centrifugation after standing at 37°C for 6 hours for non-targeted metabolomics detection, and the types and contents of oligopeptides in the supernatant were finally determined to determine the oligopeptide metabolic capacity of EcN-P and EcN-Pc-OPT. Here, we analyzed the non-targeted metabolomics results in positive and negative ion modes, respectively, to draw the result graph of the metabolic capacity of EcN-P and EcN-Pc-OPT oligopeptides.

[0039] Example 8: Verification of the distribution of P. copri oligopeptide transporter Pc-OPT in other species

[0040] Using the amino acid sequence of P. copri oligopeptide transporter Pc-OPT (shown in SEQ ID NO.2) as a template, BlastP in NCBI was used to analyze the distribution of Prevotella copri oligopeptide transporter Pc-OPT in other species. Specifically, we selected strains with identity and coverage greater than 75%, excluded redundant items according to the taxid number, and performed distance tree of results analysis on the selected reference sequences.

[0041] Example 9: Verification of the colonization ability of EcN-P and EcN-Pc-OPT in the mouse intestine

[0042] The EcN-P and EcN-Pc-OPT strains were cultured in liquid LB medium supplemented with ampicillin resistance to an OD of 600 = 1.0, and the bacteria were collected by centrifugation and washed three times with PBS buffer, and then the 10The bacterial solution was gavaged into 6-week-old male C57BL / 6J mice (the mice were gavaged with PBS-oligopeptide buffer containing oligopeptides while being fed a normal diet), and the fecal samples of the mice were weighed 12 hours after the gavage. After the fecal samples were homogenized with PBS buffer, the obtained fecal bacterial solution was diluted and plated, and the number of EcN-P and EcN-Pc-OPT strains remaining in the initial fecal bacterial solution was calculated by counting the number of colonies on the plate and the gradient dilution multiple. Finally, the corresponding number of colonies in the unit fecal sample (number of colonies / g fecal sample) was calculated.

[0043] The above examples are only for illustrating the technical concept and features of the present invention, and their purpose is to enable people familiar with the technology to understand the content of the present invention and implement it accordingly, and they cannot be used to limit the protection scope of the present invention. Any equivalent transformation or modification made according to the spirit and essence of this invention should be included in the protection scope of the present invention.

Claims

1. An oligopeptide transporter derived from Prevotella, characterized in that It has the amino acid sequence shown in SEQ ID NO.

1.

2. A nucleic acid, characterized in that The oligopeptide transporter derived from Prevotella as claimed in claim 1 is encoded, and its nucleotide sequence is shown as SEQ ID NO.

2.

3. A plasmid, characterized in that Containing the nucleic acid according to claim 2.

4. A recombinant Escherichia coli, characterized in that Transformed to contain the plasmid described in claim 3.

5. Use of the oligopeptide transporter of Prevotella according to claim 1 in improving the oligopeptide transport capacity of Escherichia coli and its intestinal colonization ability.

6. A pharmaceutical composition or food additive comprising the recombinant Escherichia coli according to claim 4.

7. A method for enhancing the intestinal colonization ability of Escherichia coli, characterized in that: The method comprises the steps of: utilizing the recombinant Escherichia coli described in claim 4 to enhance its colonization ability in the intestine through the oligopeptide transporter expressed by the recombinant Escherichia coli.

Citation Information

Patent Citations

  • Grass carp bacteria small peptide recognition receptor as well as preparation method and application thereof

    CN114671945A

  • Oligopeptide expression and purification method based on Escherichia coli display and intein cleavage

    CN115197953A

  • Recombinant Escherichia Coli Strains

    US20160015781A1

  • Bacteria engineered to treat diseases that benefit from reduced gut inflammation and / or tightened gut mucosal barrier

    US20240110192A1

  • Isolated Candida albicans oligopeptide transporter gene

    US6441134B1